Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events
- PMID: 18006337
- PMCID: PMC2409285
- DOI: 10.1016/j.neuroimage.2007.09.064
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events
Abstract
Background: We report functional and structural brain indicators that may precede the onset of dementia in individuals with Down's syndrome (DS).
Methods: Middle-aged adults with DS (n=19), a group known to be at high risk for dementia, were studied with (1) positron emission tomography (PET) to determine cerebral glucose metabolic rate (GMR), (2) structural magnetic resonance imaging (MRI) to determine gray matter volume (GM), and (3) ratings of potential dementia indicators based on a structured interview of caregiver observations designed to evaluate individuals with low intelligence.
Results: Although none of the participants showed clinical signs of dementia, ratings of dementia indicators were correlated to both functional and structural imaging. The strongest correlations (p<.05, corrected for multiple comparisons) included the combination of higher GMR and decreased GM volume in parts of the temporal cortex, including the parahippocampus/hippocampus, in the thalamus, caudate, and frontal lobe (BA 47).
Interpretation: The combination of increased GMR overlapping with less gray matter in these areas may be consistent with a compensatory brain response to an early stage of the disease process.
Figures
Similar articles
-
Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia.Neurology. 2003 Dec 23;61(12):1673-9. doi: 10.1212/01.wnl.0000098935.36984.25. Neurology. 2003. PMID: 14694028 Clinical Trial.
-
MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia.Am J Psychiatry. 1999 Apr;156(4):564-8. doi: 10.1176/ajp.156.4.564. Am J Psychiatry. 1999. PMID: 10200735
-
Dementia in Down's syndrome: cerebral glucose utilization, neuropsychological assessment, and neuropathology.Neurology. 1988 Jun;38(6):938-42. doi: 10.1212/wnl.38.6.938. Neurology. 1988. PMID: 2966900
-
NIH Conference. Alzheimer's disease and Down's syndrome: new insights.Ann Intern Med. 1985 Oct;103(4):566-78. doi: 10.7326/0003-4819-103-4-566. Ann Intern Med. 1985. PMID: 2864010 Review.
-
Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention.J Alzheimers Dis. 2007 Mar;11(1):61-76. doi: 10.3233/jad-2007-11110. J Alzheimers Dis. 2007. PMID: 17361036 Review.
Cited by
-
Distinct neuroanatomical and neuropsychological features of Down syndrome compared to related neurodevelopmental disorders: a systematic review.Front Neurosci. 2023 Aug 3;17:1225228. doi: 10.3389/fnins.2023.1225228. eCollection 2023. Front Neurosci. 2023. PMID: 37600012 Free PMC article.
-
Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.Int Rev Res Dev Disabil. 2022;62:227-263. doi: 10.1016/bs.irrdd.2022.05.006. Epub 2022 Jul 21. Int Rev Res Dev Disabil. 2022. PMID: 37396708 Free PMC article.
-
Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.Neuron. 2022 Jul 6;110(13):2063-2079. doi: 10.1016/j.neuron.2022.04.001. Epub 2022 Apr 25. Neuron. 2022. PMID: 35472307 Free PMC article. Review.
-
A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia.Dement Geriatr Cogn Dis Extra. 2021 Dec 27;11(3):324-332. doi: 10.1159/000520880. eCollection 2021 Sep-Dec. Dement Geriatr Cogn Dis Extra. 2021. PMID: 35111192 Free PMC article. Review.
-
The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.J Clin Med. 2021 Oct 3;10(19):4582. doi: 10.3390/jcm10194582. J Clin Med. 2021. PMID: 34640600 Free PMC article. Review.
References
-
- Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002;159(5):738–745. - PubMed
-
- Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11(6 Pt 1):805–821. - PubMed
-
- Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage. 2001;14(6):1238–1243. - PubMed
-
- Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A. Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res. 1997;41(Pt 2):152–164. - PubMed
-
- Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, Barta PE, Chan MD, Smith PD, Jerram M, Pearlson GD. MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am J Psychiatry. 1999;156(4):564–568. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HD037427-03/HD/NICHD NIH HHS/United States
- R01 AG021912/AG/NIA NIH HHS/United States
- R01 AG016593/AG/NIA NIH HHS/United States
- R01 HD037427-02/HD/NICHD NIH HHS/United States
- P50 AG016573-04/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG005142-159011/AG/NIA NIH HHS/United States
- P50-AG16593/AG/NIA NIH HHS/United States
- R01 HD037427-05/HD/NICHD NIH HHS/United States
- R01 HD-37427/HD/NICHD NIH HHS/United States
- P50 AG016573-05/AG/NIA NIH HHS/United States
- R01 HD037427-04/HD/NICHD NIH HHS/United States
- AG21912/AG/NIA NIH HHS/United States
- R01 HD037427-01A1/HD/NICHD NIH HHS/United States
- R01 HD037427/HD/NICHD NIH HHS/United States
- P50 AG016573-06/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
